Tango Therapeutics (TNGX) Receivables (2020 - 2022)

Tango Therapeutics' Receivables history runs 3 years deep, the most recent figure standing at $2.0 million for Q4 2022.

• On a quarterly basis, Receivables changed 0.0% year-over-year to $2.0 million in Q4 2022; TTM through Dec 2022 was $2.0 million, a 0.0% change from a year earlier, with the FY2022 full-year figure at $2.0 million, changed 0.0% from the prior year.
• Receivables steadied at $2.0 million in Q4 2022 per TNGX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Receivables topped out at $8.0 million in Q3 2021 and bottomed at $2.0 million in Q4 2020.
• The 3-year median for Receivables is $2.0 million (2020), against an average of $2.9 million.
• Across the five-year window, Receivables changed 0.0% in 2021 and sank 75.0% in 2022, its largest moves.
• Year by year, Receivables stood at $2.0 million in 2020, then changed by 0.0% to $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022.
• Per Business Quant, the three latest TNGX Receivables figures stand at $2.0 million (Q4 2022), $2.0 million (Q3 2022), and $2.0 million (Q2 2022).